Market closed
Moderna/$MRNA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Ticker
$MRNA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
5,600
Website
Moderna Metrics
BasicAdvanced
$15B
Market cap
-
P/E ratio
-$5.82
EPS
1.69
Beta
-
Dividend rate
Price and volume
Market cap
$15B
Beta
1.69
52-week high
$170.47
52-week low
$35.80
Average daily volume
10M
Financial strength
Current ratio
4.392
Quick ratio
3.831
Long term debt to equity
10.933
Total debt to equity
11.361
Interest coverage (TTM)
-48.09%
Management effectiveness
Return on assets (TTM)
-9.55%
Return on equity (TTM)
-17.52%
Valuation
Price to revenue (TTM)
2.967
Price to book
1.27
Price to tangible book (TTM)
1.28
Price to free cash flow (TTM)
-3.811
Growth
Revenue change (TTM)
-44.29%
Earnings per share change (TTM)
-35.66%
3-year revenue growth (CAGR)
-24.55%
3-year earnings per share growth (CAGR)
-29.65%
What the Analysts think about Moderna
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Moderna stock.
Moderna Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Moderna Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Moderna News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Moderna stock?
Moderna (MRNA) has a market cap of $15B as of December 24, 2024.
What is the P/E ratio for Moderna stock?
The price to earnings (P/E) ratio for Moderna (MRNA) stock is 0 as of December 24, 2024.
Does Moderna stock pay dividends?
No, Moderna (MRNA) stock does not pay dividends to its shareholders as of December 24, 2024.
When is the next Moderna dividend payment date?
Moderna (MRNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Moderna?
Moderna (MRNA) has a beta rating of 1.69. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.